RA
XERS icon

Rosalind Advisors’s Xeris Biopharma Holdings XERS Stock Holding History

Rosalind Advisors’s Portfolio XERS Stock Details XERS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$18.7M Buy
3,231,700
+1,120,000
+53% +$7.43M 7.68% 2
2025
Q4 		$16.6M Buy
2,111,700
+315,934
+18% +$2.49M 6.04% 4
2025
Q3 		$14.6M Sell
1,795,766
-359,828
-17% -$2.39M 5.17% 6
2025
Q2 		$10.1M Sell
2,155,594
-340,392
-14% -$1.56M 4.87% 6
2025
Q1 		$13.7M Sell
2,495,986
-609,009
-20% -$2.46M 6.68% 3
2024
Q4 		$10.5M Hold
3,104,995
– – 5.67% 5
2024
Q3 		$8.85M Sell
3,104,995
-15,175
-0.5% -$39K 5.87% 7
2024
Q2 		$7.02M Buy
3,120,170
+300,000
+11% +$605K 5.55% 6
2024
Q1 		$6.23M Sell
2,820,170
-723,515
-20% -$1.87M 5.83% 5
2023
Q4 		$8.33M Buy
+3,543,685
New +$6.54M 6.97% 4

Other funds holding XERS

BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $127B AUM 43.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $70.4B AUM 20.22% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $134B AUM 35.51% 1-Year Est. Return